Edge Rewrite
// HTMLRewriter · presentation

This page was redesigned at the edge.

Cloudflare fetched the original article and streamed it through HTMLRewriter to apply an entirely new visual system without rebuilding the source page.

Jump to content

Reposal

From Wikipedia, the free encyclopedia
Reposal
Clinical data
Other namesReposamal, 5-Ethyl-5-(bicyclo(3.2.1)octenyl)barbituric acid
ATC code
Identifiers
  • 5-bicyclo[3.2.1]oct-2-en-3-yl-5-ethylpyrimidine-2,4,6(1H,3H,5H)-trione
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC14H18N2O3
Molar mass262.309 g·mol−1
3D model (JSmol)
  • O=C1NC(=O)NC(=O)C1(CC)C=3C[C@H]2C[C@H](CC2)C=3
  • InChI=1S/C14H18N2O3/c1-2-14(11(17)15-13(19)16-12(14)18)10-6-8-3-4-9(5-8)7-10/h6,8-9H,2-5,7H2,1H3,(H2,15,16,17,18,19)/t8-,9+/m0/s1 checkY
  • Key:MKELYWOVSPVORM-DTWKUNHWSA-N checkY
 X markNcheckY (what is this?)  (verify)

Reposal is a barbiturate derivative invented in the 1960s in Denmark. It has sedative, hypnotic and anticonvulsant properties, and was used primarily for the treatment of insomnia.[1][2][3]

References

[edit]
  1. Kessing SV, Tarding F, Thomsen AC (December 1963). "Reposal, A New Hypnotic. I. Pharmacodynamic Activity". Ugeskrift for Laeger (in Danish). 125: 1735–8. PMID 14103836.
  2. Kessing SV, Tarding F, Thomsen AC (December 1963). "Reposal, A New Hypnotic. Ii. Clinical Effects". Ugeskrift for Laeger (in Danish). 125: 1739–41. PMID 14103837.
  3. Nielsen P, Tarding F (1968). "The metabolic fate of 5-(bicyclo-3,2,1,-oct-2-en-2-yl)-5-ethyl barbituric acid, (Reposal)". Acta Pharmacologica et Toxicologica. 26 (6): 521–30. doi:10.1111/j.1600-0773.1968.tb00471.x. PMID 5756387.